Abstract
Background and Aims: Endoscopic outcomes have become important measures of eosinophilic esophagitis (EoE) disease activity, including as an endpoint in randomized controlled trials (RCTs). We evaluated the operating properties of endoscopic measures for use in EoE RCTs. Methods: Modified Research and Development/University of California Los Angeles appropriateness methods and a panel of 15 international EoE experts identified endoscopic items and definitions with face validity that were used in a 2-round voting process to define simplified (all items graded as absent or present) and expanded versions (additional grades for edema, furrows, and/or exudates) of the EoE Endoscopic Reference Score (EREFS). Inter- and intrarater reliability of these instruments (expressed as intraclass correlation coefficients [ICC]) were evaluated using paired endoscopy video assessments of 2 blinded central readers in patients before and after 8 weeks of proton pump inhibitors, swallowed topical corticosteroids, or dietary elimination. Responsiveness was measured using the standardized effect size (SES). Results: The appropriateness of 41 statements relevant to EoE endoscopic activity (endoscopic items, item definitions and grading, and other considerations relevant for endoscopy) was considered. The original and expanded EREFS demonstrated moderate-to-substantial inter-rater reliability (ICCs of .472-.736 and .469-.763, respectively) and moderate-to-almost perfect intrarater reliability (ICCs of .580-.828 and .581-.828, respectively). Strictures were least reliably assessed (ICC, .072-.385). The original EREFS was highly responsive (SES, 1.126 [95% confidence interval {CI}, .757-1.534]), although both expanded versions of EREFS, scored based on worst affected area, were numerically most responsive to treatment (expanded furrows: SES, 1.229 [95% CI, .858-1.643]; all items expanded: SES, 1.252 [95% CI, .880-1.667]). The EREFS and its modifications were not more reliably scored by segment and also not more responsive when proximal and distal EREFSs were summed. Conclusions: EREFS and its modifications were reliable and responsive, and the original or expanded versions of the EREFS may be preferred in RCTs. Disease activity scored based on the worst affected area optimizes reliability and responsiveness.
Original language | English (US) |
---|---|
Pages (from-to) | 1126-1137.e2 |
Journal | Gastrointestinal endoscopy |
Volume | 95 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2022 |
ASJC Scopus subject areas
- Gastroenterology
- Radiology Nuclear Medicine and imaging
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Gastrointestinal endoscopy, Vol. 95, No. 6, 06.2022, p. 1126-1137.e2.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis
AU - Ma, Christopher
AU - Bredenoord, Albert J.
AU - Dellon, Evan S.
AU - Alexander, Jeffrey A.
AU - Biedermann, Luc
AU - Hogan, Malcolm
AU - Guizzetti, Leonardo
AU - Zou, Guangyong
AU - Katzka, David A.
AU - Chehade, Mirna
AU - Falk, Gary W.
AU - Furuta, Glenn T.
AU - Gupta, Sandeep K.
AU - Kagalwalla, Amir F.
AU - Schoepfer, Alain M.
AU - Miehlke, Stephan
AU - Moawad, Fouad J.
AU - Peterson, Kathryn
AU - Gonsalves, Nirmala P.
AU - Straumann, Alex
AU - Wechsler, Joshua B.
AU - Rémillard, Julie
AU - Shackelton, Lisa M.
AU - Almonte, Hector S.
AU - Feagan, Brian G.
AU - Jairath, Vipul
AU - Hirano, Ikuo
N1 - Funding Information: DISCLOSURE: The following authors disclosed financial relationships: C. Ma: Consultant for AVIR Pharma Inc and Alimentiv Inc; speaker for AVIR Pharma Inc. A. J. Bredenoord: Research support from Norgine, Nutricia, Thelial, SST, and Bayer; speaker and consultant for AstraZeneca, Medtronic, Laborie, Alimentiv, Celgene, DrFalkPharma, Arena, Esocap, Calypso, and Regeneron. E. S. Dellen: Research support from Adare/Ellodi, Allakos, AstraZeneca, Banner, Holoclara. GlaxoSmithKline, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Abbott, Abbvie, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv Inc, Salix, Sanofi, and Shire/Takeda. J. A. Alexander: Received research support from Regeneron, Adare, Arena, Celegene, and Ellode; consultant for Alimentiv; financial interest in Meritage Pharmacia. L. B Biedermann: Consultant and/or Falk Foundation, Vifor AG, Esocap AG, Sanofi-Aventis AG, and Calypso Biotech SA. M. Hogan, L. Guizzetti, J. Rémillard: Employee of Alimentiv Inc. G. Zou, L. M. Shackelton: Consultant for Alimentiv Inc. D. A. Katzka: Consultant for Takeda and Celgene. M. Chehade: Research support from Regeneron, Allakos, Shire, AstraZeneca, and Danone; consultant for Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, Ellodi, Phathom, and Bristol Myers Squibb. G. W. Falk: Research support from Adare/Ellodi, Arena, Allakos, Celgene/Receptos/BMS, Lucid, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Arena, Celgene/Receptos/BMS, Lucid, Regeneron, Sanofi, and Shire/Takeda. G. T. Furuta: Research support from Holoclara and Arena; consultant for Takeda; cofounder of EnteroTrack. S. K. Gupta: Consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin; research support from Shire, Allakos, Adare, and National Institutes of Health U54 grant to the Consortium of Eosinophilic Gastrointestinal Disease Researchers. A. M. Schoepfer: Research support from Adare/Ellodi, AstraZeneca, Receptos/BMS, Dr Falk Pharma, Regeneron, and Vifor Pharma; consultant for Adare/Ellodi, Amgen, AstraZeneca, Celgene/Receptos/BMS, Dr Falk Pharma, GlaxoSmithKline, Gossamer Bio, Regeneron, Sanofi-Genzyme, and Vifor Pharma. S. Miehlke: Consultant for Dr Falk Pharma, EsoCap, Sanofi-Regeneron, and Celgene; Falk Foundation/Falk Foundation. F. J. Moawad: Consultant for Medtronic, Shire/Takeda, and Sanofi. K. Peterson: Research support from Adare/Ellodi, Allakos, AstraZeneca, Receptos/BMS, Regeneron, Shire/Takeda, and Chobani; consultant for Adare/Ellodi, Allakos, Alladapt, AstraZeneca, Celgene/Receptos/BMS, Regeneron, Sanofi, and Shire/Takeda. N. P. Gonsalves: Consultant for Allakos, Sanofi-Regeneron, Abbvie, Astra-Zeneca, and Nutriticia; royalties from Up-to-Date. A. Straumann: Consultant for Allakos, Astra-Zeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentec, Shire, and Tillotts. J. B. Wechsler: Consultant for Allakos, Regeneron, and Sanofi/Genzyme. B. G. Feagan: Consultant for AbbVie, AdMIRx, AgomAB Therapeutics, Akebia, Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc, Arena Pharma, Avir, Azora Therapeutics, Boehringer-Ingelheim, Boston Pharma, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Everest Clinical Research Corp, Eli Lilly, Equillium, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Glenmark, Gossamer Pharma, GSK, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, ImmunExt, Imhotex, Intact Therapeutics, Janssen, Japan Tobacco Inc, Kaleido Biosciences, Leadiant, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Otsuka, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, REDX, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB Pharma, VHsquared Ltd, Viatris, Ysios, and Zealand Pharma; Speaker's Bureau for AbbVie, Janssen, and Takeda; Member, Scientific Advisory Board for AbbVie, Amgen, Boehringer-Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, and GSK; Stock shareholder in Gossamer Pharma; Employee, Western University and Alimentiv Inc. V. Jairath: Consultant for AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, GlaxoSmithKline, Genetech, Gilead, Janssen, Merck, Mylan, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Topivert; speaker for Abbvie, Ferring, Janssen Pfizer Shire, and Takeda. I. Hurano: Research support from Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/BMS, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Sanofi, and Shire/Takeda. All other authors disclosed no financial relationships. Funding Information: DISCLOSURE: The following authors disclosed financial relationships: C. Ma: Consultant for AVIR Pharma Inc and Alimentiv Inc; speaker for AVIR Pharma Inc. A. J. Bredenoord: Research support from Norgine, Nutricia, Thelial, SST, and Bayer; speaker and consultant for AstraZeneca, Medtronic, Laborie, Alimentiv, Celgene, DrFalkPharma, Arena, Esocap, Calypso, and Regeneron. E. S. Dellen: Research support from Adare/Ellodi, Allakos, AstraZeneca, Banner, Holoclara. GlaxoSmithKline, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Abbott, Abbvie, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv Inc, Salix, Sanofi, and Shire/Takeda. J. A. Alexander: Received research support from Regeneron , Adare, Arena, Celegene, and Ellode; consultant for Alimentiv; financial interest in Meritage Pharmacia. L. B Biedermann: Consultant and/or Falk Foundation, Vifor AG, Esocap AG, Sanofi-Aventis AG, and Calypso Biotech SA. M. Hogan, L. Guizzetti, J. Rémillard: Employee of Alimentiv Inc. G. Zou, L. M. Shackelton: Consultant for Alimentiv Inc. D. A. Katzka: Consultant for Takeda and Celgene. M. Chehade: Research support from Regeneron, Allakos, Shire, AstraZeneca, and Danone; consultant for Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca , Sanofi, Ellodi, Phathom, and Bristol Myers Squibb . G. W. Falk: Research support from Adare/Ellodi, Arena, Allakos, Celgene/Receptos/BMS, Lucid, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Arena, Celgene/Receptos/BMS, Lucid, Regeneron, Sanofi, and Shire/Takeda. G. T. Furuta: Research support from Holoclara and Arena; consultant for Takeda; cofounder of EnteroTrack. S. K. Gupta: Consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin; research support from Shire, Allakos, Adare, and National Institutes of Health U54 grant to the Consortium of Eosinophilic Gastrointestinal Disease Researchers. A. M. Schoepfer: Research support from Adare/Ellodi, AstraZeneca, Receptos/BMS, Dr Falk Pharma, Regeneron, and Vifor Pharma; consultant for Adare/Ellodi, Amgen, AstraZeneca, Celgene/Receptos/BMS, Dr Falk Pharma, GlaxoSmithKline , Gossamer Bio, Regeneron, Sanofi-Genzyme, and Vifor Pharma. S. Miehlke: Consultant for Dr Falk Pharma, EsoCap, Sanofi-Regeneron, and Celgene; Falk Foundation/Falk Foundation. F. J. Moawad: Consultant for Medtronic, Shire/Takeda, and Sanofi. K. Peterson: Research support from Adare/Ellodi, Allakos, AstraZeneca, Receptos/BMS, Regeneron, Shire/Takeda, and Chobani; consultant for Adare/Ellodi, Allakos, Alladapt, AstraZeneca, Celgene/Receptos/BMS, Regeneron, Sanofi, and Shire/Takeda. N. P. Gonsalves: Consultant for Allakos, Sanofi-Regeneron, Abbvie, Astra-Zeneca, and Nutriticia; royalties from Up-to-Date. A. Straumann: Consultant for Allakos, Astra-Zeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentec, Shire, and Tillotts. J. B. Wechsler: Consultant for Allakos, Regeneron, and Sanofi/Genzyme. B. G. Feagan: Consultant for AbbVie, AdMIRx, AgomAB Therapeutics, Akebia, Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc, Arena Pharma, Avir, Azora Therapeutics, Boehringer-Ingelheim, Boston Pharma, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Everest Clinical Research Corp, Eli Lilly, Equillium, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Glenmark, Gossamer Pharma, GSK, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, ImmunExt, Imhotex, Intact Therapeutics, Janssen, Japan Tobacco Inc, Kaleido Biosciences, Leadiant, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Otsuka, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, REDX, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB Pharma, VHsquared Ltd, Viatris, Ysios, and Zealand Pharma; Speaker's Bureau for AbbVie, Janssen, and Takeda; Member, Scientific Advisory Board for AbbVie, Amgen, Boehringer-Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, and GSK; Stock shareholder in Gossamer Pharma; Employee, Western University and Alimentiv Inc. V. Jairath: Consultant for AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, GlaxoSmithKline, Genetech, Gilead, Janssen, Merck, Mylan, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Topivert; speaker for Abbvie, Ferring, Janssen Pfizer Shire, and Takeda. I. Hurano: Research support from Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/BMS, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Sanofi, and Shire/Takeda. All other authors disclosed no financial relationships. Publisher Copyright: © 2022 American Society for Gastrointestinal Endoscopy
PY - 2022/6
Y1 - 2022/6
N2 - Background and Aims: Endoscopic outcomes have become important measures of eosinophilic esophagitis (EoE) disease activity, including as an endpoint in randomized controlled trials (RCTs). We evaluated the operating properties of endoscopic measures for use in EoE RCTs. Methods: Modified Research and Development/University of California Los Angeles appropriateness methods and a panel of 15 international EoE experts identified endoscopic items and definitions with face validity that were used in a 2-round voting process to define simplified (all items graded as absent or present) and expanded versions (additional grades for edema, furrows, and/or exudates) of the EoE Endoscopic Reference Score (EREFS). Inter- and intrarater reliability of these instruments (expressed as intraclass correlation coefficients [ICC]) were evaluated using paired endoscopy video assessments of 2 blinded central readers in patients before and after 8 weeks of proton pump inhibitors, swallowed topical corticosteroids, or dietary elimination. Responsiveness was measured using the standardized effect size (SES). Results: The appropriateness of 41 statements relevant to EoE endoscopic activity (endoscopic items, item definitions and grading, and other considerations relevant for endoscopy) was considered. The original and expanded EREFS demonstrated moderate-to-substantial inter-rater reliability (ICCs of .472-.736 and .469-.763, respectively) and moderate-to-almost perfect intrarater reliability (ICCs of .580-.828 and .581-.828, respectively). Strictures were least reliably assessed (ICC, .072-.385). The original EREFS was highly responsive (SES, 1.126 [95% confidence interval {CI}, .757-1.534]), although both expanded versions of EREFS, scored based on worst affected area, were numerically most responsive to treatment (expanded furrows: SES, 1.229 [95% CI, .858-1.643]; all items expanded: SES, 1.252 [95% CI, .880-1.667]). The EREFS and its modifications were not more reliably scored by segment and also not more responsive when proximal and distal EREFSs were summed. Conclusions: EREFS and its modifications were reliable and responsive, and the original or expanded versions of the EREFS may be preferred in RCTs. Disease activity scored based on the worst affected area optimizes reliability and responsiveness.
AB - Background and Aims: Endoscopic outcomes have become important measures of eosinophilic esophagitis (EoE) disease activity, including as an endpoint in randomized controlled trials (RCTs). We evaluated the operating properties of endoscopic measures for use in EoE RCTs. Methods: Modified Research and Development/University of California Los Angeles appropriateness methods and a panel of 15 international EoE experts identified endoscopic items and definitions with face validity that were used in a 2-round voting process to define simplified (all items graded as absent or present) and expanded versions (additional grades for edema, furrows, and/or exudates) of the EoE Endoscopic Reference Score (EREFS). Inter- and intrarater reliability of these instruments (expressed as intraclass correlation coefficients [ICC]) were evaluated using paired endoscopy video assessments of 2 blinded central readers in patients before and after 8 weeks of proton pump inhibitors, swallowed topical corticosteroids, or dietary elimination. Responsiveness was measured using the standardized effect size (SES). Results: The appropriateness of 41 statements relevant to EoE endoscopic activity (endoscopic items, item definitions and grading, and other considerations relevant for endoscopy) was considered. The original and expanded EREFS demonstrated moderate-to-substantial inter-rater reliability (ICCs of .472-.736 and .469-.763, respectively) and moderate-to-almost perfect intrarater reliability (ICCs of .580-.828 and .581-.828, respectively). Strictures were least reliably assessed (ICC, .072-.385). The original EREFS was highly responsive (SES, 1.126 [95% confidence interval {CI}, .757-1.534]), although both expanded versions of EREFS, scored based on worst affected area, were numerically most responsive to treatment (expanded furrows: SES, 1.229 [95% CI, .858-1.643]; all items expanded: SES, 1.252 [95% CI, .880-1.667]). The EREFS and its modifications were not more reliably scored by segment and also not more responsive when proximal and distal EREFSs were summed. Conclusions: EREFS and its modifications were reliable and responsive, and the original or expanded versions of the EREFS may be preferred in RCTs. Disease activity scored based on the worst affected area optimizes reliability and responsiveness.
UR - http://www.scopus.com/inward/record.url?scp=85127472451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127472451&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2022.01.014
DO - 10.1016/j.gie.2022.01.014
M3 - Article
C2 - 35120883
AN - SCOPUS:85127472451
SN - 0016-5107
VL - 95
SP - 1126-1137.e2
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 6
ER -